Treatment of gastric cancer;Therapie des magenkarzinoms

Onkologie

Volumn 31, Issue SUPPL. 5, 2008, Pages 32-39

  Lordick, Florian ^a   Ridwelski, Karsten ^b   Al Batran, Salah Eddin ^c   Trarbach, Tanja ^d   Schlag, Peter M ^e   Piso, Pompiliu ^f  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Klinikum Magdeburg

^c KRANKENHAUS NORDWEST   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAPATINIB; OXALIPLATIN; PANITUMUMAB; TRASTUZUMAB;

ACUTE HEART INFARCTION; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; METASTASIS; PREOPERATIVE CARE; PROGNOSIS; STOMACH CANCER; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 56849100975     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163075     Document Type: Conference Paper

References (30)

1. Siewert JR, et al: Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-461.
2. Cunningham D, et al. for the MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
3. Boige V, et al: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007;25(18 suppl):4510.
4. Jansen E, et al: Postoperative chemoradiotherapy in gastric cancer: A phase I-II study of radiotherapy with weekly cisplatin and daily capecitabine. ASCO GI 2008;abstr 55.
5. Mobayed M, et al: Activity and safety of carboplatin and paclitaxel followed by capecitabine and radiation as adjuvant therapy for gastric cancer. ASCO GI 2008;abstr 61.
6. Mulcahy MF, et al: Capecitabine and oxaliplatin for resectable esophageal adenocarcinoma: Preliminary results of a phase II study. ASCO GI 2008;abstr 45.
7. Janunger KG, et al: Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002;168:597-608.
8. Lordick F, Siewert JR: Recent advances in multimodal treatment for gastric cancer: A review. Gastric Cancer 2005;8:78-85.
9. Sakuramoto S, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
10. Nakajima T, et al: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-1476.
11. Macdonald JS, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
12. Macdonald JS, et al: Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). Proc Gastrointestinal Cancers Symposium, San Francisco, 2004, abstract 6.
13. Ajani JA, et al: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24:3953-3958.
14. Lutz MP, et al: Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HDFU/ FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: Randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007;25:2580-2585.
15. Cunningham D, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
16. Kang Y, et al: Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol 2006;24(18 suppl):LBA4018.
17. Al-Batran SE, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442.
18. Trumper M, et al: Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 2006;42:827-834.
19. Van Cutsem E, et al. for the V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
20. Lorenzen S, et al: Split-dose docetaxel, cisplatin, and leucovorin/5-fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Results of a phase II trial. Ann Oncol 2007;18:1673-1679.
21. Al-Batran SE, et al: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is active and has a favorable safety profile for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: A phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2008, in press.
22. Cortes-Funes H, et al: Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/ amplification. J Clin Oncol 2007;25(18 suppl):4613.
23. Lordick F, et al: Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI group. J Clin Oncol 2007;25(18 suppl):abstr 4514.
24. Pinto C, et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-517.
25. Moehler MH, et al: Cetuximab with irinotecan/Na-Fa/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a nonrandomised multi-centre AIO phase II study. ASCO GI 2008;abstr 102.
26. Shah MA, et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206.
27. Enzinger PC, et al: Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. ASCO GI 2008;abstr 97.
28. Enzinger PC, et al: Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO GI 2006;abstr 68.
29. Cohenuram MK, et al: FOLFOX6 and bevacizumab for metastatic esophageal, gastroesophageal, and gastric adenocarcinoma: A single institution's initial clinical experience. ASCO GI 2008;abstr 74.
30. Jhawer MP, et al: Interim results of a phase II study of modified docetaxel, cisplatin, fluorouracil, and bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ASCO GI 2008;abstr 109